Alterations in gonadotropin secretion in middle-aged persistent-estrous rats following LHRH agonist treatment.
During aging female rats enter an anovulatory condition with chronically elevated circulating levels of estrogen described as persistent estrus (PE). Since this endocrine state is dramatically different from the fluctuating steroid milieu of young regularly cycling females, interpretations of altered neuroendocrine responses in aged rats have been difficult to attribute to aging per se. In the present study, young cyclic and middle-aged PE rats were treated with an LHRH agonist, [DTrp6,Pro9-NHEt]-LHRH, continuously (2.5 micrograms/h) for 12 days to suppress gonadotropin and ovarian steroid secretion. On the evening of the first day of LHRH agonist (LHRH-AG) treatment both young cyclic and middle-aged PE rats showed marked (p < 0.01) increases in plasma LH and FSH followed by progressive decreases in gonadotropin secretion which reached significantly (p < 0.05) lower levels than pretreatment values by day 7. LHRH-AG treatment significantly (p < 0.01) reduced circulating 17 beta-estradiol (E2) levels in both young and PE rats while progesterone concentrations did not change. Following LHRH-AG treatment, ovariectomy (OVX) resulted in increases of plasma LH and FSH that were delayed and attenuated in PE rats as compared to those of young females. When compared to nontreated rats, 12 days of LHRH-AG treatment in both young and PE females had a minimal and transient effect on the post-OVX gonadotropin responses, suggesting that the endocrine status immediately prior to OVX does not profoundly influence the post-OVX responses in young cyclic and middle-aged PE rats. Furthermore, LHRH-AG treatment does not appear to have permanent inhibitory effects on the hypothalamic-pituitary axis.(ABSTRACT TRUNCATED AT 250 WORDS)
Department of Obstetrics and Gynecology, Medical College of Virginia, Richmond 23298-0034, USA.
D W
DW
Matt
M L
ML
Tedeschi
T E
TE
Sayles
D000375:Aging / Q000502:physiology*; D000818:Animals; D003692:Delayed-Action Preparations; D004958:Estradiol / Q000097:blood; D004971:Estrus / Q000187:drug effects / Q000502:physiology*; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006062:Gonadotropins / Q000378:metabolism*; D007986:Luteinizing Hormone / Q000097:blood; D010052:Ovariectomy; D011374:Progesterone / Q000097:blood; D051381:Rats; D011966:Receptors, LHRH / Q000819:agonists*; D013997:Time Factors; D017329:Triptorelin Pamoate / Q000031:analogs & derivatives* / Q000494:pharmacology
D003692:Delayed-Action Preparations; D006062:Gonadotropins; D011966:Receptors, LHRH; D017329:Triptorelin Pamoate; D011374:Progesterone; D004958:Estradiol; C019176:Tryptal; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone